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Case Report

A 19 year-old female college student presented to her pediatrician’s office after experiencing three weeks of fatigue, abdominal
pain, and nausea. At that time, the patient was diagnosed with
a urinary tract infection and a viral illness and was given a
prescription for Keflex. Over the next three days, the patient’s
symptoms worsened, and she developed weakness, shortness
of breath, and anorexia. She also noticed yellowing of her skin
and darkening of her urine, which prompted her to go to the
emergency department at an outside hospital. At the outside
hospital, many laboratory results were abnormal and her clinical
condition worsened. She was transferred to the intensive care
unit at Thomas Jefferson University Hospital (TJUH) for further
evaluation and treatment.
The patient had no significant past medical, surgical history, or
family history. She took a multivitamin and an oral contraceptive
daily and denied the use of any herbal supplements or overthe-counter medications. She had no known drug allergies.
She reported social alcohol and marijuana use, most recently
one month ago, and denied tobacco use. She denied recent
sexual activity or foreign travel. Review of systems was positive
for shortness of breath, nausea, vomiting, abdominal pain,
decreased urine output, dark urine, muscle cramps, headache,
dizziness, jaundice, anorexia, and a six-pound weight gain over
three weeks.
Upon admission, the patient’s vital signs were within normal
limits, and her physical exam was notable for jaundice, scleral
icterus, diffuse abdominal tenderness and distension, ascites, and
bilateral lower extremity pitting edema. Routine laboratories were
notable for a white blood cell count of 51.9 B/L, a hemoglobin
of 7.0 g/dL, and INR of 3.92, and creatinine of 2.5 mg/dL, a total
bilirubin of 52.1 mg/dL, a direct bilirubin of 21.8 mg/dL, and
alkaline phosphatase of less than 5 IU/L, a lactate dehydrogenase
of 963 IU/L, a haptoglobin of less than 6 mg/dL, and a lactate of
28.4 mg/dL.

Hospital course

With all clinical and laboratory findings pointing towards
fulminant hepatic failure, a search for the cause was initiated.
Tests for hepatitis B, hepatitis C, HIV, EBV, CMV, parvovirus,
syphilis, SLE, autoimmune hepatitis, and acetomenopheninduced liver toxicity were all negative. The suspicion for Wilson
Disease was high, but ceruloplasmin, urine and serum copper
levels were still pending. Over the first two days of the patient’s
hospitalization, her condition worsened, and it became clear that
she would require a liver transplant for survival. The patient was
listed as status one for orthotopic liver transplantation with the
presumptive diagnosis of Wilson Disease.
On the third day of hospitalization at TJUH, the patient began
to get more confused and somnolent. The patient also became
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anuric with severe and progressive renal failure, requiring
hemodialysis. The patient developed respiratory distress and was
intubated. Additionally, she became hypotensive, and pressors
were initiated. The patient was now severely acidemic, had a
lactate of 197.7 mg/dL, an INR of 6.77 with diffuse bleeding,
and one of her pupils was fixed and dilated. The patient was
taken to the operating room for hepatectomy, despite the fact
that the donor liver transplant had not yet arrived at TJUH. Two
hours later, the donor liver arrived and the patient underwent
transplantation.
After the transplant was completed, the patient improved
clinically, and her laboratory values also began to return towards
normal. Her neurologic and cognitive function returned to
baseline. She required one return trip to the operating room for
bile duct reconstruction and was discharged from the hospital
on post-operative day 19. The final diagnosis of Wilson Disease
was made post-operatively when the patient’s serum copper
came back at 270mcg/dL (normal range: 80-155), and her urine
copper came back at 2371.4mcg/dL (normal range: 0.2-8).
Ceruloplasmin was within normal limits.

Discussion

Wilson Disease, also known as hepatolenitcular degeneration,
is an autosomal recessive disorder caused by mutations in the
ATP7B gene, which codes for a membrane-bound coppertransporting ATPase. When functioning properly, this ATPase
transports copper into the bile so that it can be excreted from the
body via the gastrointestinal tract. In patients with Wilson disease,
copper cannot be excreted into the bile and thus accumulates in
the liver bound to a protein called metallothionein. Mutations
in the ATP7B gene also impair the incorporation of copper
into ceruloplasmin. Excess copper in the liver causes increased
generation of free radicals, which lead to liver damage. This
progressive liver damage eventually leads to cirrhosis. A cirrhotic
liver is unable to maintain the huge amount of accumulated
copper, so the copper begins to leak into the bloodstream where
it accumulates in and damages other tissues.1
Wilson Disease affects one in 30,000 live births. Symptoms rarely
occur before age six and are almost always present by age thirty,
with a mean age of onset of sixteen. Two times more females
with Wilson Disease progress to fulminant hepatic failure than
do their male counterparts.1, 2
Neurologic symptoms, such as Parkinsonism, dystonia, cerebellar
dysfunction, or pyramidal signs are the presenting features of
Wilson Disease in 69% of patients. These neurologic manifestations result from accumulation of copper in the basal ganglia.
Neurologic symptoms are often associated with psychiatric
symptoms such as anxiety, depression, and pyschosis, but
psychiatric symptoms are rarely seen in the absence of neurologic
symptoms. Approximately 15% of patients with Wilson Disease
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present with signs and symptoms of cirrhosis, while another
5% have asymptomatic liver function test abnormalities. It
is much less common for patients to present with isolated
musculoskeletal complaints such as premature osteoporosis or
osteoarthritis. It is also uncommon for patients to present with
fulminant hepatic failure, as the patient in this case did.2
Kayser-Fleischer rings are brownish-gray rings seen around the
iris that consist of copper deposits in Descemet’s membrane
that are commonly seen in Wilson Disease. They can only be
appreciated on a slit lamp exam and are present in greater than
90% of Wilson Disease patients with neurologic and psychiatric
symptoms. In patients with Wilson Disease without neurologic
or psychiatric symptoms, Kayser-Fleischer rings will only be
present 50% to 60% of the time.3
The patient in this case presented with fulminant hepatic
failure which is unusual for Wilson Disease. Clinicians
must have a high index of suspicion in order to make this
diagnosis. Children and young adults who present with liver
failure and also have a Coombs negative hemolytic anemia, a
coagulopathy that is unresponsive to vitamin K, renal failure,
mild AST and ALT elevations, and/or alkaline phosphatase
levels of less than 40 IU/L should be considered to have
Wilson Disease until proven otherwise, as this presentation
is associated with a very high mortality rate if not treated
appropriately and in a timely fashion.4
The gold standard for diagnosing Wilson Disease is a liver
biopsy with quantitative copper assay. However, this is rarely
the first step in making the diagnosis. Patients with suspected
Wilson Disease must first have liver function tests including
coagulation studies, a complete blood count, a ceruloplasmin
level, a 24-hour urine copper assay, and a thorough physical
exam including a slit lamp exam. Patients with Kayser-Fleischer
rings, a decreased serum ceruloplasmin, or urine copper levels
greater than 40 mcg/day need a liver biopsy to confirm the
diagnosis. Copper levels of greater than 250 mcg/g on liver
biopsy are consistent with a diagnosis of Wilson Disease. The
work-up and diagnosis of Wilson Disease is a lengthy process
and in patients with fulminant hepatic failure like the one in this
case, treatment must be initiated before a diagnosis is finalized
in order to give the patient the greatest chance of survival.3, 4

chelating agent penicillamine or with zinc, to remove copper
that has already accumulated in the liver and prevent the further
accumulation. For symptomatic patients, the copper chelating
agent trientine should be used until laboratory tests confirm
that copper levels have returned to the normal range, at which
point patients may be switched to maintenance therapy with
penicillamine or zinc. Patients with Wilson Disease must remain
on copper chelation therapy for life, for if is stopped, copper will
begin to reaccumulate. For patients that present with fulminant
hepatic failure, emergent liver transplant is the only treatment
available, and it is curative.4
Wilson Disease has an excellent prognosis if diagnosed and
treated early. Neurologic and hepatic symptoms resolve with
appropriate treatment. It is unclear as to whether there is an
increased risk of hepatocellular carcinoma in patients with
Wilson Disease. 5 Prognosis for patients who present with
fulminant hepatic failure is poor and depends on the availability
of liver transplantation.
As Wilson Disease is a genetic disorder, screening of siblings
and children of patients with the disease is necessary. Possible
patients should be screened with slit-lamp examination, liver
function tests, serum ceruloplasmin and copper levels, and 24hour urine copper excretion. If any of these tests are abnormal,
a liver biopsy should be done to confirm the diagnosis.
Occasionally, genetic testing may be performed, if the specific
mutation of the ATP7B gene in the proband is known. When a
patient’s screening test for Wilson Disease is positive, treatment
should be started immediately to ensure the best possible
outcome.
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Treatment of patients with Wilson Disease depends on whether
or not the patient is symptomatic. Asymptomatic patients
diagnosed via screening tests should be treated with the copper
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